http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Adaptive Fault-Tolerant Neural Control for Large-scale Systems with Actuator Faults
Jian-Ye Gong,Bin Jiang,Qi-Kun Shen 제어·로봇·시스템학회 2019 International Journal of Control, Automation, and Vol.17 No.6
The active adaptive fault-tolerant neural control problem is discussed for large-scale uncertain systems against actuator faults. The unknown interconnections among subsystems are assumed to be nonlinear, not traditional linear. A general actuator fault model is proposed, which integrates bias and gain time-varying faults. Then, based on Lyapunov stability theory, a novel fault diagnostic algorithm and accommodation scheme are proposed, where the assumptions in the existing works are removed and fault-tolerant controller singularity problem is avoided. Finally, simulation results of near space vehicle show the efficiency of the presented control approach.
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, Razvan,Lee, Jeeyun,Nebozhyn, Michael,Kim, Kyoung-Mee,Ting, Jason C,Wong, Swee Seong,Liu, Jiangang,Yue, Yong Gang,Wang, Jian,Yu, Kun,Ye, Xiang S,Do, In-Gu,Liu, Shawn,Gong, Lara,Fu, Jake,Jin, Nature Publishing Group 2015 Nature medicine Vol. No.
Gastric cancer, a leading cause of cancer-related deaths, is a heterogeneous disease. We aim to establish clinically relevant molecular subtypes that would encompass this heterogeneity and provide useful clinical information. We use gene expression data to describe four molecular subtypes linked to distinct patterns of molecular alterations, disease progression and prognosis. The mesenchymal-like type includes diffuse-subtype tumors with the worst prognosis, the tendency to occur at an earlier age and the highest recurrence frequency (63%) of the four subtypes. Microsatellite-unstable tumors are hyper-mutated intestinal-subtype tumors occurring in the antrum; these have the best overall prognosis and the lowest frequency of recurrence (22%) of the four subtypes. The tumor protein 53 (TP53)-active and TP53-inactive types include patients with intermediate prognosis and recurrence rates (with respect to the other two subtypes), with the TP53-active group showing better prognosis. We describe key molecular alterations in each of the four subtypes using targeted sequencing and genome-wide copy number microarrays. We validate these subtypes in independent cohorts in order to provide a consistent and unified framework for further clinical and preclinical translational research.